... Now, J&J wants to enlist Ben Venue's help again. As The Wall Street Journal reports, J&J's new Doxil plan would rely on Ben Venue to produce the drug, in areas of its Bedford plant that are now available and approved for use. Another supplier would handle sterile filtration and aseptic filling, to make sure the drug isn't contaminated.
J&J has asked FDA and its counterparts in the EU to approve the new process, the WSJ says. That would amp up Doxil supplies in the short term, giving J&J time to find a long-term manufacturer for Doxil.